These people will be administered a drug to see if it will slow or stop the impacts of Alzheimer’s disease.
Dr. Reisa Sperling is the Director at the Center for Alzheimer’s Research and Treatment.
“This is a new study and what’s particularly new about it is trying it in people who don’t yet have symptoms of Alzheimer’s disease. So we’re really trying to change the way we think about Alzheimer’s disease and focus on prevention, rather than most of the trials which unfortunately have not done so well at later stages of Alzheimer’s disease.”
Dr. Sperling says the study has been going on since 2014, and results are expected in 2020.
Sperling says the study will cost around $140 million and is funded by the National Institutes of Health.